subtheme 1c), with 8 of 60 (13%) respondents reporting that Ozempic treatment was associated with decreased cravings, particularly for sugary and greasy foods (median 10.0, MAD 0.0)
At Vermont Med Spa in Los Angeles, Dr
Patients with a history of thyroid tumors such as medullary thyroid carcinoma (MTC) and MEN 2 syndrome (multiple endocrine neoplasia type 2 syndrome) should not take Zepbound
VR and AI represent interesting possibilities for scaling therapy access and creating experiences that traditional approaches cannot deliver
PT-141 Research# PT-141 completed the full drug development pathway: RECONNECT trials : Two Phase 3 pivotal trials in premenopausal women with HSDD demonstrated statistically significant improvements in sexual desire scores compared to placebo, with a meaningful increase in satisfying sexual events FDA approval : Approved June 21, 2019, as Vyleesi for HSDD in premenopausal women Male sexual dysfunction : Earlier trials explored PT-141 for male erectile dysfunction, though this indication was not pursued to approval Dose limitations : FDA label restricts use to no more than 8 doses per month and recommends against use in patients with uncontrolled hypertension or cardiovascular disease Post-marketing : Ongoing pharmacovigilance with established adverse event reporting The regulatory gap between MT-2 and PT-141 is the fundamental differentiator: PT-141 has undergone the rigorous efficacy and safety evaluation required for FDA approval, while MT-2 has not
When a drug receives FDA approval, it means that after rigorous testing in clinical trials, it has been shown to be both safe and effective for treating a specific condition
